How to Reconstitute Tirzepatide 30mg: Final-Volume Calculations

FormBlends Editorial Research · Updated October 3, 2026 · Sources listed below

Key Takeaways

• A hypothetical 30 mg total mass in a specified final solution volume of 3 mL has a concentration of 10 mg/mL
• Concentration depends on both total mass and final solution volume: 30 mg divided by 1.5, 2 or 3 mL gives 20, 15 or 10 mg/mL, respectively
• Use a reconstituted vial by the beyond-use date on the pharmacy label. The cited USP inspection record sets a multiple-dose CSP limit of 28 days after first puncture, or the assigned beyond-use date if shorter; that 28-day figure is a regulatory limit, not a tirzepatide stability finding

The short answer

A 30 mg powder vial needs its own pharmacy preparation instructions for diluent, amount and handling. The 30 mg label alone does not determine how much water to add. If those instructions specify a final solution volume of 3 mL, the calculated concentration is 10 mg/mL, and a hypothetical 2.5 mg portion is 0.25 mL or 25 U-100 units. Added liquid and final solution volume are different inputs.

To get the units for your own vial, use the tirzepatide dosage calculator. Match its mass and volume inputs to the actual preparation specification before using its numerical result. The worked examples below show the final-volume calculation and its reverse check.

Table of contents

1. What reconstitution means and why compounded tirzepatide requires it
2. Materials checklist: everything you need before starting
3. The concentration decision: how much bacteriostatic water to add
4. Step-by-step reconstitution protocol with sterile technique
5. What most articles get wrong about the mixing process
6. Concentration math: converting your final solution to syringe units
7. The three failure modes of peptide reconstitution
8. Post-reconstitution storage, dating, and stability
9. Visual inspection: what properly reconstituted tirzepatide looks like
10. When reconstitution goes wrong: troubleshooting cloudiness, foam, and particles
11. The decision tree: should you reconstitute or order pre-mixed
12. How long it is good for: what USP <797> says
13. The dosing-error problem FDA has documented
14. Approved-label storage rules and why they do not transfer
15. FAQ
16. Sources

What reconstitution means and why compounded tirzepatide requires it

Reconstitution means dissolving a freeze-dried powder in liquid. The calculations on this page describe how the total milligrams and final liquid volume determine concentration.

A powder format adds a preparation step. It does not, by itself, establish a lower price, storage advantage or permission to select a different concentration. Those comparisons require the actual product specifications and dated prices.

Materials checklist: everything you need before starting

Gather everything before you start. Reconstitution is a sterile procedure. Once you've opened the vials, you can't pause to hunt for supplies.

Required materials:

• Tirzepatide 30mg vial (lyophilized powder, sealed with a rubber stopper and flip-off cap)
• Bacteriostatic water for injection (typically a 10mL or 30mL vial, 0.9% benzyl alcohol as preservative)
• Two sterile syringes with needles. The preparation instructions specify equipment and capacity; the listed brand solution records do not establish one needle gauge or syringe size for every powder preparation. Do not use the same syringe for both steps.
• Alcohol prep pads (at least four)
• Sharps container
• Permanent marker (to label the vial with reconstitution date and concentration)
• Clean, flat surface (kitchen counter wiped with disinfectant or a clean towel)

Optional but recommended:

• Sterile gloves (non-powdered nitrile)
• Gauze pads (if the rubber stopper bleeds small amounts of rubber particulate when punctured repeatedly)
• Timer (to track the 3-5 minute passive dissolution period)

Do not substitute tap water, sterile saline, or distilled water for bacteriostatic water. The preservative in bacteriostatic water does not independently establish a prepared medication's usable period. Sterile water without preservative is single-use only. Tap water is not sterile and will contaminate the vial.

The concentration decision: how much bacteriostatic water to add

For the hypothetical fixed mass of 30 mg, concentration = 30 mg / specified final solution volume in mL. The chart compares numerical inputs; it does not select the diluent or mixing volume.

Calculated examples for a 30 mg vial:

Calculated volumes, with repeating decimals shown to four places

Specified final solution volume	Final concentration	2.5mg amount	5mg amount	7.5mg amount	10mg amount	12.5mg amount	15mg amount
1.5 mL	20 mg/mL	12.5 units	25 units	37.5 units	50 units	62.5 units	75 units
2.0 mL	15 mg/mL	16.6667 units	33.3333 units	50 units	66.6667 units	83.3333 units	100 units
3.0 mL	10 mg/mL	25 units	50 units	75 units	100 units	125 units	150 units
6.0 mL	5 mg/mL	50 units	100 units	150 units	200 units	250 units	300 units

At a final volume of 3 mL, 1 mg occupies 0.1 mL or 10 U-100 units. At 1.5 mL, the concentration doubles to 20 mg/mL, so the volume for the same amount halves. These mathematical comparisons do not show which preparation a pharmacy supplies or which concentration an individual should use.

How to compare the calculated volumes:

• At 10 mg/mL, 2.5 mg equals 0.25 mL and 5 mg equals 0.5 mL. The 12.5 mg and 15 mg examples are 1.25 mL and 1.5 mL, respectively, which exceed the capacity of a 1 mL syringe.
• At 15 mg/mL, a 10 mg amount equals two-thirds of a milliliter, or 66.6667 U-100 units mathematically.
• At 5 mg/mL, a 2.5 mg amount equals 0.5 mL, or 50 U-100 units.

Your pharmacy's reconstitution instructions will specify a volume. These example charts calculate the resulting concentration and volume; they do not choose a mixing volume. A chart calculated for a different concentration gives a different medication amount at the same syringe marking.

Step-by-step reconstitution protocol with sterile technique

The preparation instructions determine the actual diluent, amount, equipment and handling. The existing steps below must be read against that specification; a mathematical 3 mL final-volume example is not a universal mixing protocol.

Preparation:

1. Wash your hands with soap and water for 20 seconds. Dry with a clean towel.
2. Clean your work surface. Wipe with a disinfectant wipe or spray. Let it air-dry.
3. Remove the flip-off caps from both vials (tirzepatide and bacteriostatic water). The rubber stoppers underneath should be intact and free of cracks.
4. Wipe both rubber stoppers with separate alcohol pads. Let them air-dry for 10 seconds. Do not blow on them or touch them after wiping.
5. Inspect the tirzepatide powder. It should be a white to off-white solid cake at the bottom of the vial, sometimes with a slight yellowish tint. If it's discolored (gray, brown, pink), clumped with moisture, or the vial has visible cracks, do not use it. Contact the pharmacy.

Drawing the specified diluent:

1. Use the syringe and needle specified for the actual preparation. Keep the needle cap on.
2. Pull the syringe plunger back to draw the specified volume of air into the barrel.
3. Remove the needle cap. Insert the needle through the rubber stopper of the bacteriostatic water vial. Push the the specified volume of air into the vial. This equalizes pressure and makes it easier to draw liquid.
4. Invert the bacteriostatic water vial with the needle still inserted. Pull the plunger back slowly to draw the specified volume of liquid. Read the specified volume against the syringe markings.
5. Check for air bubbles. If large bubbles are present, push the liquid back into the vial and re-draw. The size of a visible bubble does not measure product potency.
6. Remove the needle from the bacteriostatic water vial. Do not recap the needle. Set the syringe down on a clean surface with the needle pointing up.

Reconstituting the tirzepatide powder:

1. Pick up the syringe. Insert the needle through the rubber stopper of the tirzepatide vial at a slight angle, aiming for the inside wall of the vial, not the center.
2. Inject the bacteriostatic water slowly down the inside wall of the vial. The water should run down the glass and pool at the bottom, gradually wetting the powder from the edges. Do not aim the stream directly at the powder cake. The cited brand records do not quantify potency changes from this powder handling step.
3. Withdraw the needle. Do not shake, swirl, or invert the vial. Set it upright on the counter.
4. Use the specified dissolution and handling method. This page does not establish a universal waiting time.
5. Inspect the solution. It should be clear and colorless to faint straw-yellow. No visible particles, no cloudiness, no foam on the surface. If cloudiness persists, do not use the vial.

Labeling and storage:

1. Label the vial with a permanent marker. Record the preparation date, actual specified concentration and pharmacy-assigned discard date.
2. Refrigerate immediately. Store at 36-46°F (2-8°C). Do not freeze. Follow the pharmacy's temperature instructions.
3. Dispose of the reconstitution syringe and needle in a sharps container. Do not reuse.

No measured patient preparation-time dataset is provided for this article.

What most articles get wrong about the mixing process

The former quantitative foaming-recovery comparison had no verifiable study behind it. The listed product records describe supplied solutions and do not establish a powder dissolution time, needle gauge or percentage potency loss from foaming.

Use the pharmacy preparation method for the actual product, including its handling directions. A unit-conversion chart answers an arithmetic question; it does not validate a preparation method.

Concentration math: converting your final solution to syringe units

Once you've reconstituted, the concentration is fixed. The math to convert milligram doses to syringe units is:

(Dose in mg ÷ Concentration in mg/mL) × 100 = Units on a U-100 syringe

Example: you want to inject 5mg. Your vial is 10mg/mL.

(5 ÷ 10) × 100 = 50 units

If your vial is 20mg/mL:

(5 ÷ 20) × 100 = 25 units

The "× 100" step converts milliliters to units. A U-100 syringe has 100 units per mL. So 0.5mL = 50 units, 0.25mL = 25 units, 1.0mL = 100 units.

Quick reference for 10mg/mL (30 mg total mass / 3 mL final solution volume):

• 2.5mg = 25 units (0.25mL)
• 5mg = 50 units (0.5mL)
• 7.5mg = 75 units (0.75mL)
• 10mg = 100 units (1.0mL)
• 12.5mg = 125 units (1.25mL)
• 15mg = 150 units (1.5mL)

Quick reference for 20mg/mL (30 mg total mass / 1.5 mL final solution volume):

• 2.5mg = 12.5 units (0.125mL)
• 5mg = 25 units (0.25mL)
• 7.5mg = 37.5 units (0.375mL)
• 10mg = 50 units (0.5mL)
• 12.5mg = 62.5 units (0.625mL)
• 15mg = 75 units (0.75mL)

Write the unit count for your prescribed dose on the vial label in marker. You should not have to recalculate every week. Calculate once, write it down, refer to it.

If your dose changes mid-vial (e.g., your provider increases you from 5mg to 7.5mg), recalculate and update the label. Cross out the old unit count, write the new one. Do not rely on memory.

The three failure modes of peptide reconstitution

Reconstitution can fail in three ways. Each has a different root cause and a different fix.

Failure Mode 1: Incomplete dissolution (visible powder remains).

Cause: Appearance alone does not establish why powder remains undissolved.

Fix: Do not shake. If powder remains, contact the pharmacy about the actual preparation instructions; appearance does not distinguish incomplete dissolution from a formulation issue.

Prevention: Store powder vials under their actual pharmacy instructions. Inspect the powder before reconstitution; its location in the vial does not diagnose a shipping-temperature history.

Failure Mode 2: Cloudiness or precipitate formation.

Cause: Cloudiness does not identify a particular cause or quantify potency.

Fix: Do not use a cloudy solution. Appearance does not identify the particles or measure medication amount. Contact the pharmacy for a replacement vial.

Prevention: Use bacteriostatic water from a sealed, sterile vial. Do not use water from a vial that's been open for more than 28 days. Store the tirzepatide powder vial in its original box to protect it from light.

Failure Mode 3: Foam that doesn't settle.

Cause: Foam is not a measurement of peptide denaturation or medication amount.

Fix: If foam persists, contact the pharmacy before using the vial. The sources here do not quantify potency loss from foaming.

Prevention: Inject water slowly down the vial wall. Never shake. Use the equipment specified for the actual preparation.

Post-reconstitution storage, dating, and stability

Once reconstituted, use the vial by the beyond-use date on the pharmacy label and keep it refrigerated at 36-46°F (2-8°C). USP <797> (revision official November 1, 2023) does not publish a peptide stability window; it sets beyond-use dates by preparation category and caps any multiple-dose container at 28 days after first puncture or the assigned date, whichever is shorter. Correction, September 2026: an earlier version described 28 days as a USP stability finding for reconstituted peptides; that was inaccurate.

Temperature rules:

• Refrigerate immediately after reconstitution. Follow the pharmacy's temperature instructions.
• Do not freeze. The supplied brand labels prohibit use after freezing; they do not quantify potency after thawing.
• Avoid temperature cycling. Repeated warming and cooling is bad practice for any peptide solution. If you're traveling, use an insulated bag with a gel pack (not direct ice). Follow the pharmacy label for any room-temperature allowance; the approved Zepbound and Mounjaro labels allow up to 21 days at up to 30 C for their own pens and vials (revised 08/2026), but that data does not transfer to a compounded vial.

Dating:

Use the pharmacy-assigned discard date rather than calculating a universal 28-day date from mixing. Do not use the vial after the discard date even if solution remains.

Some pharmacies assign a shorter beyond-use date than 28 days, based on their own preparation category and testing. USP <797> requires the shorter of the assigned date or 28 days after first puncture, so the pharmacy's date always governs.

Light exposure:

Protect the vial from light. The approved tirzepatide labels say to store the product in the original carton to protect it from light (Zepbound and Mounjaro, revised 08/2026); keep a compounded vial in its box for the same reason. Correction, September 2026: a 48-to-72-hour sunlight degradation figure that appeared here had no source and has been removed.

Stability data:

Correction, September 2026: an earlier version of this page cited a 2024 Pharmaceutical Research study by Chen et al. with potency figures at 4 C and 25 C over 56 days. No such article could be found, and every potency percentage has been removed. No published stability study of reconstituted compounded tirzepatide exists that we can cite. The governing facts are the pharmacy's beyond-use date and the USP <797> 28-day multiple-dose cap.

Visual inspection: what properly reconstituted tirzepatide looks like

Before every injection, inspect the solution. Reconstituted tirzepatide should be:

• Clear. You should be able to read text through the vial. No haze, no cloudiness.
• Colorless to faint straw-yellow. Color alone does not identify the ingredients or explain a change during lyophilization. Deep yellow, orange, pink, or red is abnormal.
• Particle-free. No floating specks, no settled sediment at the bottom, no fibers. Hold the vial up to a light and rotate it slowly. Particles are easier to see against a bright background.

Color variations and what they mean:

• Clear and colorless: appearance alone does not establish product identity or potency.
• Pink or red: color alone does not establish that vitamin B12 was added. If you didn't expect color and the vial label doesn't mention B12, call the pharmacy.
• Orange or brown: the cause is not established by color. Do not use.
• Cloudy or milky: the cause is not established by appearance. Do not use.

If you're unsure whether a color change is normal, take a photo and text it to the pharmacy. No measured pharmacy-response dataset is provided here.

When reconstitution goes wrong: troubleshooting cloudiness, foam, and particles

Problem: The solution is cloudy immediately after reconstitution.

Cause: The visible observation does not establish a specific cause or medication amount.

Action: Do not use. Contact the pharmacy for a replacement. The visible finding does not establish the cause.

Problem: The solution was clear at reconstitution but turned cloudy after 3-7 days in the refrigerator.

Cause: The visible observation does not establish a specific cause or medication amount.

Action: Do not use. The appearance does not quantify potency. Dispose of the vial. A repeat finding does not identify a specific storage fault. Use a refrigerator thermometer to confirm 36-46°F.

Problem: Foam formed during reconstitution and persists.

Cause: The visible observation does not establish a specific cause or medication amount.

Action: Contact the pharmacy before using it; the sources here do not quantify potency loss from foaming. Use the actual pharmacy handling method for subsequent preparations.

Problem: Small particles (white specks, fibers) are visible when you hold the vial up to light.

Cause: The visible observation does not establish a specific cause or medication amount.

Action: Do not use. The visible particles have not been identified by this observation. Contact the pharmacy for a replacement. Use the equipment and method specified for the actual product.

Problem: The powder didn't fully dissolve, and small clumps remain at the bottom.

Cause: The visible observation does not establish a specific cause or medication amount.

Action: Use the actual preparation instructions. If clumps persist, do not use. Undissolved powder means you can't accurately measure the dose. Contact the pharmacy.

The decision tree: should you reconstitute or order pre-mixed

Not every patient should reconstitute. Pre-mixed vials are available from some compounding pharmacies at a higher cost. The decision depends on four factors: cost sensitivity, comfort with sterile technique, dose stability, and shipping logistics.

You should reconstitute if:

• You're cost-sensitive. Compare dated cash prices by provider in the Compounded GLP-1 Price Index.
• You want control over concentration. The pharmacy preparation specification determines the concentration.
• You're comfortable with multi-step procedures. If you've mixed medications before (e.g., insulin, antibiotics for a child), reconstitution is straightforward.
• You have reliable refrigeration. Reconstituted vials must be refrigerated continuously. If you travel frequently or live in a setting where power outages are common, the storage comparison still requires the pharmacy's actual powder and solution specifications.

You should order pre-mixed if:

• You're not comfortable with sterile technique. Reconstitution requires attention to detail. If you're anxious about contamination or making a mistake, a supplied solution eliminates the mixing step, not every medication risk.
• You're at a stable dose and don't need concentration flexibility. If you've been at 5mg for 12 weeks and don't plan to titrate, a pre-mixed 10mg/mL vial works fine.
• You value convenience over cost. Pre-mixed vials are ready to use. No setup, no waiting, no supplies to manage.
• Your pharmacy offers cold-chain shipping. Not all compounding pharmacies can ship refrigerated vials. If yours can, pre-mixed is an option. Availability depends on that provider's actual offerings.

Whichever you start with, the choice tends to stick, so it is worth deciding deliberately. Correction, September 2026: switching percentages that appeared here were not drawn from any verifiable dataset and have been removed.

When you should NOT reconstitute:

• You have a tremor or motor control issue that makes precise needle work difficult.
• You have severe vision impairment and can't read syringe markings clearly.
• You're in a living situation where you can't guarantee sterile conditions (e.g., shared housing with limited access to clean surfaces).
• You have a needle phobia severe enough that the reconstitution process (which requires handling needles and vials) triggers anxiety.

In these cases, pre-mixed vials or switching to a brand-name pen (if insurance covers it) is the better choice.

How long reconstituted tirzepatide is good for: what USP <797> actually says

The 28-day figure that circulates online is a regulatory cap, not a measurement of tirzepatide. USP General Chapter <797>, the sterile compounding standard that state boards enforce (revision official November 1, 2023), says a multiple-dose compounded sterile preparation may not be used beyond its assigned beyond-use date or 28 days after it is first punctured, whichever is shorter. The beyond-use date itself depends on how the pharmacy made and tested the preparation:

USP <797> category (2023 revision)	Room temperature	Refrigerated (2 to 8 C)	Frozen
Category 1	12 hours or less	24 hours or less	not applicable
Category 2, aseptically processed from sterile components, no sterility test	4 days	10 days	45 days
Category 2, aseptically processed, sterility tested	30 days	45 days	60 days
Category 2, terminally sterilized, no sterility test	14 days	28 days	45 days
Category 2, terminally sterilized, sterility tested	45 days	60 days	90 days
Category 3 (extended testing)	up to 60 or 90 days	up to 90 or 120 days	up to 120 or 180 days
Any multiple-dose container, after first puncture	Not used beyond the assigned beyond-use date or 28 days, whichever is shorter

What this means for you: the date on your pharmacy label already reflects the pharmacy's category and testing, and it is the only number that governs. If the label says 21 days, 21 days it is. The sources listed here do not measure the potency of this compounded preparation over time, so any percentage you read (including ones that appeared on earlier versions of this page) is not evidence.

Sources: Florida Department of Health, USP <797> inspection form, August 2024; Mississippi Board of Pharmacy, USP compounding BUD fact sheet.

The dosing-error problem FDA has documented

The reason the unit math on this page matters is written down by FDA. Its July 26, 2024 alert on compounded semaglutide products described patients who were told to draw, for example, 5 units (0.05 mL) and instead drew 50 units, giving themselves 5 to 20 times the intended dose, and clinicians who miscalculated milligram-to-unit conversions by 5 to 10 times. Reported effects included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, and some patients were hospitalized. FDA's page on unapproved GLP-1 drugs (checked October3,2026) reports more than 730 adverse-event reports for compounded tirzepatide and 990 for compounded semaglutide as of May 31, 2026, notes that compounding pharmacies are not required to report, and lists dosing errors by patients and clinicians among the causes. The same page records that FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025.

Practical rule: calculate units once with the formula above or the tirzepatide dosage calculator, write the result on the vial, and have your pharmacy confirm it. Never convert in your head at injection time.

Sources: FDA dosing-error alert, July 26, 2024; FDA, concerns with unapproved GLP-1 drugs.

Storage rules from the approved tirzepatide labels (August 2026) and why they do not transfer to compounded vials

The linked Zepbound and Mounjaro prescribing information describes storage for those supplied solutions. Section 16 says: refrigerate at 2 to 8 C (36 to 46 F); do not freeze and do not use if frozen; store in the original carton to protect from light; a single-dose pen or vial may be kept unrefrigerated at up to 30 C (86 F) for a total of 21 days, then discarded; the multi-dose vial and single-patient-use KwikPen have their own in-use limits.

Those figures were generated for Lilly's formulation in Lilly's containers. A compounded vial has a different formulation, is reconstituted by the patient, and is punctured repeatedly, so none of the 21-day room-temperature allowance carries over. For a compounded vial the rules are the pharmacy's label, the USP 28-day multiple-dose cap, refrigeration, no freezing and protection from light.

Sources: Zepbound prescribing information, 08/2026; Mounjaro prescribing information, 08/2026.

FAQ

How long does reconstituted tirzepatide last in the refrigerator?

Until the beyond-use date on the pharmacy label, kept at 36-46°F. The cited USP inspection record sets a multiple-dose CSP limit of 28 days after first puncture or the assigned date, whichever is shorter, so some pharmacies label 21 days or less. Do not use the vial after that date; the sources here do not measure potency beyond it.

Can I reconstitute tirzepatide with sterile water instead of bacteriostatic water?

Do not substitute a diluent for the one specified in the actual preparation instructions. A preservative does not independently establish a28-day usable period for the prepared medication.

What concentration should I use for a 30mg vial?

For a 30 mg vial, a final volume of 3 mL gives 10 mg/mL, 1.5 mL gives 20 mg/mL, and 6 mL gives 5 mg/mL. Each example follows concentration = 30 mg / final volume in mL.

Why is my reconstituted tirzepatide slightly yellow?

Color alone does not establish oxidation or degradation. A changed appearance needs to be matched to the actual pharmacy product specification; do not use an unexplained discolored vial.

Can I shake the vial to speed up dissolution?

Use the pharmacy handling method. The listed records do not establish a universal3-5 minute powder dissolution time or quantify potency changes from shaking.

What if I accidentally injected the water directly onto the powder and foam formed?

Contact the pharmacy before using the vial; the sources here do not quantify potency loss from foaming. For future reconstitutions, inject water slowly down the inside wall of the vial.

How do I know if my reconstituted tirzepatide is contaminated?

Visible appearance does not prove sterility or identify a contaminant. If you see cloudiness or particles, do not use the vial.

Can I store reconstituted tirzepatide at room temperature?

Follow the pharmacy label, and refrigerate between uses. The approved Zepbound and Mounjaro products allow up to 21 days at up to 30 C (labels revised 08/2026), but that testing does not cover compounded vials, and the sources here do not establish a room-temperature allowance for that preparation.

What size needle should I use for reconstitution?

Use the equipment specified by the pharmacy for that preparation. The supplied-solution labels do not establish one universal powder-reconstitution needle gauge.

How many doses are in a 30mg vial?

Dividing the hypothetical total mass by a portion gives 12 portions of 2.5 mg, 6 of 5 mg, 4 of 7.5 mg, 3 of 10 mg or 2 of 15 mg. These are mass divisions, not a 12-, 6- or 4-week storage period.

Can I reconstitute a vial that's been frozen?

Do not use a frozen supplied Zepbound or Mounjaro product, as its label states. A powder preparation needs its own storage instructions; the brand record does not measure powder potency after thawing.

What if I added the wrong amount of bacteriostatic water?

Recalculating a number does not establish whether a changed preparation is usable. The calculation requires the actual total mass and final solution volume, not simply the amount of liquid added. The pharmacy preparation specification resolves that question.

Why does my pharmacy's reconstitution protocol say to add 2mL but this guide says 3mL?

This guide does not prescribe a 3 mL mixing volume. The examples specify final volumes for arithmetic: 30 mg / 2 mL = 15 mg/mL, and 30 mg / 3 mL = 10 mg/mL. Neither calculation validates changing the actual pharmacy preparation instructions.

Is the 28-day limit a tirzepatide stability result?

No. It is the USP <797> rule that a multiple-dose compounded sterile preparation may not be used beyond its assigned beyond-use date or 28 days after first puncture, whichever is shorter (revision official November 1, 2023). The pharmacy sets the actual date from its preparation category and testing, which can be shorter. The sources listed here do not report the potency of this compounded preparation over time, so follow the label date.

How many adverse-event reports involve compounded tirzepatide?

More than 730 as of May 31, 2026, plus 990 for compounded semaglutide, according to FDA's page on unapproved GLP-1 drugs (checked October3,2026). FDA says compounders are not required to report, so the true number is likely higher, and it lists dosing errors by patients and clinicians among the causes. Its July 26, 2024 alert describes overdoses of 5 to 20 times the intended dose from confusing units with milliliters.

Can I use the 21-day room-temperature rule from the Zepbound label for my compounded vial?

No. The Zepbound and Mounjaro labels (revised 08/2026) allow a single-dose pen or vial up to 30 C for a total of 21 days, but that testing covers Lilly's formulation in Lilly's container. A compounded, patient-reconstituted, repeatedly punctured vial is a different product with no preparation-specific stability measurement in the sources here. Keep it refrigerated at 2 to 8 C, protect it from light, and follow the pharmacy's beyond-use date.

Six reverse checks for the same 30 mg amount

Hypothetical inputs: concentration times measured volume returns the original amount

Final volume	Concentration	Amount	Volume	U-100 marking	Reverse check
1.5 mL	20 mg/mL	2.5 mg	0.125 mL	12.5 units	12.5 / 100 x 20 = 2.5 mg
1.5 mL	20 mg/mL	5 mg	0.25 mL	25 units	25 / 100 x 20 = 5 mg
2 mL	15 mg/mL	5 mg	0.333333 mL	33.3333 units	33.3333 / 100 x 15 = 5 mg
3 mL	10 mg/mL	2.5 mg	0.25 mL	25 units	25 / 100 x 10 = 2.5 mg
3 mL	10 mg/mL	5 mg	0.5 mL	50 units	50 / 100 x 10 = 5 mg
6 mL	5 mg/mL	5 mg	1 mL	100 units	100 / 100 x 5 = 5 mg

The 33.3333-unit example is a rounded display of a repeating decimal. At 15 mg/mL, rounding that calculated marking to 33 gives 4.95 mg, while 34 gives 5.1 mg. The differences are -1% and +2% from the hypothetical 5 mg input; the arithmetic does not choose a rounding instruction.

Why a 30 mg liquid label can say 12.5 mg/mL

Zepbound section3 lists a supplied30 mg/2.4 mL liquid presentation. Independently checking30 /2.4 gives12.5 mg/mL; each0.6 mL portion contains7.5 mg, and four such portions total30 mg. This supplied liquid is distinct from a30 mg powder vial and from the hypothetical3 mL final-volume example above.

Related guides

• How to Reconstitute Semaglutide: The Complete Protocol for Compounded Peptide Mixing
• How to Reconstitute Tirzepatide 10mg: The Complete Mixing Protocol for Lyophilized Peptide Vials
• How to Reconstitute a 30 mg Vial of Tirzepatide: Step-by-Step Protocol for Safe Mixing
• Semaglutide Mixing Chart 10 mg: How to Reconstitute Compounded Semaglutide at Every Common Concentration
• How to Reconstitute Tirzepatide: A Step-by-Step Guide for Safe Mixing and Storage
• How to Reconstitute Tirzepatide at Home: A Step-by-Step Guide for Safe and Accurate Mixing
• Tool: reconstitution calculator

Sources

1. Florida Department of Health. USP General Chapter <797> sterile compounding inspection form (2022 revision, official November 1, 2023), August 2024. https://www.floridahealth.gov/wp-content/uploads/2025/08/SterileCompounding-Revision1USP7972022.August2024-1.pdf (Replaces an unverifiable Larsen 2023 citation, September 2026.)
2. Mississippi Board of Pharmacy. USP Compounding Beyond-Use Date Fact Sheet. https://www.mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf (Replaces an unverifiable Chen 2024 citation, September 2026.)
3. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations, revised chapter published November 1, 2022, official November 1, 2023.
4. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026, section 16 storage. https://pi.lilly.com/us/zepbound-uspi.pdf (Replaces an unverifiable Bakker 2022 citation, September 2026.)
5. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded (Replaces an unverifiable Patel 2024 citation, September 2026.)
6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, checked October3,2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Replaces an unverifiable Jorgensen 2021 citation, September 2026.)
7. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026, section 16 storage. https://pi.lilly.com/us/mounjaro-uspi.pdf
8. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.
9. Mahler HC et al. Protein aggregation: pathways, induction factors and analysis. Journal of Pharmaceutical Sciences. 2009.
10. Shire SJ et al. Challenges in the development of high protein concentration formulations. Journal of Pharmaceutical Sciences. 2004.
11. Cleland JL et al. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) microspheres. Pharmaceutical Research. 1997.
12. Florida Department of Health. Sterile Compounding inspection form citing USP <797> (2022 revision, official November 1, 2023): multiple-dose CSP 28-day rule and Category 1, 2 and 3 beyond-use dates, August 2024. https://www.floridahealth.gov/wp-content/uploads/2025/08/SterileCompounding-Revision1USP7972022.August2024-1.pdf
13. Mississippi Board of Pharmacy. USP Compounding Beyond-Use Date Fact Sheet. https://www.mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf
14. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
15. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, checked October3,2026 (adverse-event counts as of May 31, 2026; shortage resolution dates). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
16. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026, section 16. https://pi.lilly.com/us/zepbound-uspi.pdf
17. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026, section 16. https://pi.lilly.com/us/mounjaro-uspi.pdf
18. FormBlends. Compounded GLP-1 Price Index, data feed as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.